Vanda Pharmaceuticals (NASDAQ:VNDA) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report published on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright began coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, October 31st. They issued a “buy” rating and a $18.00 price objective for the company.

Vanda Pharmaceuticals Trading Up 3.2 %

VNDA stock opened at $4.78 on Thursday. The firm has a 50-day moving average of $4.86 and a two-hundred day moving average of $5.22. The firm has a market capitalization of $278.71 million, a PE ratio of -17.07 and a beta of 0.76. Vanda Pharmaceuticals has a one year low of $3.46 and a one year high of $6.75.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the transaction, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 8.90% of the company’s stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Panagora Asset Management Inc. raised its holdings in shares of Vanda Pharmaceuticals by 4.3% during the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 2,509 shares in the last quarter. Verition Fund Management LLC raised its stake in shares of Vanda Pharmaceuticals by 7.8% during the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 2,927 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after buying an additional 3,473 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Vanda Pharmaceuticals by 8.8% in the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 4,449 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.